Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Relapsed/Refractory Mature T-cell and NK-cell Lymphomas
NCT03021057Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in T-cell lymphoma and natural killer cell lymphoma (NKCL), sponsored by The University of Hong Kong. Primary endpoint: Complete Remission Rate at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT03021057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021057.